Shirkey HC. Therapeutic orphans–everybody’s business. Ann Pharmacother. 2006;40(6):1174.

Article  PubMed  Google Scholar 

Domingues C, Jarak I, Veiga F, Dourado M, Figueiras A. Pediatric drug development: reviewing challenges and opportunities by tracking innovative therapies. Pharmaceutics. 2023;15(10):2431.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ward RM, Benjamin DK, Davis JM, Gorman RL, Kauffman R, Kearns GL, et al. The need for pediatric drug development. J Pediatr. 2018;192:13–21.

Article  PubMed  Google Scholar 

Ueyama E, Kaneko M, Narukawa M. Pediatric drug development in Japan: a comparison of the current situation and characteristics between Japan and Europe. Therap Innov Regul Sci. 2020;54:1152–8.

Article  Google Scholar 

National Health and Family Planning Commission, National Development and Reform Commission, Ministry of Industry and Information Technology, Ministry of Human Resources and Social Security, China Food and Drug Administration, National Administration of Traditional Chinese Medicine. Several opinions on safeguarding medication for children. 2014. Available from: http://www.nhc.gov.cn/yaozs/s3581/201405/e51354d631944fa68aac0c4d9585f291.shtml. Accessed 29 Jan 2024.

China Food and Drug Administration. Opinions on solving the backlog of drug registration applications and carry out priority review and approval (draft for comment). 2015. Available from: https://www.nmpa.gov.cn/xxgk/ggtg/ypggtg/ypqtggtg/20151113145301297.html. Accessed 29 Jan 2024.

National Health and Family Planning Commission, Ministry of Industry and Information Technology, China Food and Drug Administration. Notice on the issuance of the first paediatric drug list of encouraging research and development. 2016. Available from: http://www.nhc.gov.cn/yaozs/s3581/201605/b0ea217312314c5098d905094f7e67ee.shtml. Accessed 29 Jan 2024.

The Center for Drug Evaluation of National Medical Products Administration. Guiding principles database. Available from: https://www.cde.org.cn/zdyz/listpage/9cd8db3b7530c6fa0c86485e563f93c7. Accessed 29 Jan 2024.

General Office of the Central Committee of the Communist Party of China, General Office of the State Council. Opinions on deepening the reform of the review and approval system and encouraging innovation of pharmaceutical products and medical devices. 2017. Available from: https://www.gov.cn/gongbao/content/2017/content_5232362.htm. Accessed 29 Jan 2024.

National Medical Products Administration. Implementation measures for drug trial data protection (interim). 2018. Available from: https://www.nmpa.gov.cn/xxgk/zhqyj/zhqyjyp/20180426171801468.html. Accessed 29 Jan 2024.

Department of Pharmaceutical Administration, National Health Commission. Measures for the administration of the National Essential Drug Catalogue (Revised Draft). 2021. Available from: http://www.nhc.gov.cn/wjw/yjzj/202111/068c31b85cb7486b9f77057b3e358aae.shtml. Accessed 29 Jan 2024.

Ministry of Industry and Information Technology, National Development and Reform Commission, Ministry of Science and Technology, Commerce Department, National Health Commission, Department of emergency Management, et al. 14th Five-year plan for pharmaceutical industry development. 2022. Available from: https://www.miit.gov.cn/jgsj/ghs/zlygh/art/2022/art_5d5e4f4a945346c7ab261a9fd2669cb5.html. Accessed 29 Jan 2024.

Ministry of Science and Technology. To support and promote paediatric drug research, development and innovation from the clinical needs perspective. Jun 10, 2022. Available from: https://www.most.gov.cn/kjbgz/202206/t20220610_181037.html. Accessed 7 Apr 2024.

The Center for Drug Evaluation of the National Medical Products Administration. 2022 Annual drug review report. 2023. Available from: https://www.cde.org.cn/main/news/viewInfoCommon/849b5a642142fc00738aff200077db11. Accessed 29 Jan 2024.

Song L, Jia Y, Ran S, Li B, Xu J, Huo B, et al. Current situation of pediatric clinical trials in China: focus on trials for drug marketing application and administrative approval. BMC Pediatr. 2022;22(1):144.

Article  PubMed  PubMed Central  Google Scholar 

National Medical Products Administration. Drug trial registration and information publication platform. Available from: http://www.chinadrugtrials.org.cn/index.html. Accessed 7 Apr 2024.

Wu WW, Ji X, Mou XS, Ma XY, Huang YT, Zhang JY, et al. Trends in innovative pediatric drug development in China based on clinical trial registration data. Front Med. 2023;10:1187547.

Article  Google Scholar 

National Medical Products Administration, Announcement of the NMPA on the release of the working procedures for the addition of information for children in the labels of marketed medicinal products (trial) (No. 68 of 2023). 2023. Available from: https://www.nmpa.gov.cn/yaopin/ypggtg/20230531142548157.html. Accessed 10 Apr 2024.

The Center for Drug Evaluation of the National Medical Products Administration. Notice on publicly soliciting opinions on the Working Instructions on Addition of Information for Children in the Labels of Marketed Medicinal Products (draft for comment). 2023.Available from: https://www.cde.org.cn/main/news/viewInfoCommon/be16ee347a2d0127c8336dc8a58a8674. Accessed 10 Apr 2024.

Walsh J, Ranmal SR, Ernest TB, Liu F. Patient acceptability, safety and access: a balancing act for selecting age-appropriate oral dosage forms for paediatric and geriatric populations. Int J Pharm. 2018;536(2):547–62.

Article  CAS  PubMed  Google Scholar 

Oliviero E, Kourkopoulos G, Kimmelman J. Success rates for US and Canadian anticancer drug development efforts in pediatric oncology. Pediatr Blood Cancer. 2022;69(8): e29534.

Article  PubMed  Google Scholar 

Epps C, Bax R, Croker A, Green D, Gropman A, Klein AV, et al. Global regulatory and public health initiatives to advance pediatric drug development for rare diseases. Therap Innov Regul Sci. 2022;56(6):964–75.

Article  Google Scholar 

Yen E, Davis JM, Milne CP. Impact of regulatory incentive programs on the future of pediatric drug development. Therap Innov Regul Sci. 2019;53(5):609–14.

Article  Google Scholar 

Ledley FD, McCoy SS, Vaughan G, Cleary EG. Profitability of large pharmaceutical companies compared with other large public companies. JAMA. 2020;323(9):834–43.

Article  PubMed  PubMed Central  Google Scholar 

Lagler FB, Hirschfeld S, Kindblom JM. Challenges in clinical trials for children and young people. Arch Dis Childhood. 2020;2:1–5. https://doi.org/10.1136/archdischild-2019-318676.

Article  Google Scholar 

Eichler HG, Pignatti F, Schwarzer-Daum B, Hidalgo-Simon A, Eichler I, Arlett P, et al. Randomized controlled trials versus real world evidence: neither magic nor myth. Clin Pharmacol Ther. 2021;109(5):1212–8.

Article  PubMed  Google Scholar 

McCune S, Portman RJ. Accelerating pediatric drug development: a 2022 special issue of therapeutic innovation & regulatory science. Therap Innov Regul Sci. 2022;56(6):869–72.

Article  Google Scholar 

Klonoff DC. The new FDA real-world evidence program to support development of drugs and biologics. J Diabetes Sci Technol. 2020;14(2):345–9.

Article  PubMed  Google Scholar 

Eskola SM, Leufkens HGM, Bate A, De Bruin ML, Gardarsdottir H. Use of real-world data and evidence in drug development of medicinal products centrally authorized in Europe in 2018–2019. Clin Pharmacol Ther. 2022;111(1):310–20.

Article  PubMed  Google Scholar 

Gross AM. Using real world data to support regulatory approval of drugs in rare diseases: a review of opportunities, limitations & a case example. Curr Probl Cancer. 2021;45(4): 100769.

Article  PubMed  Google Scholar 

Bradford D, Singh H, Donoghue M. FDA regulatory considerations for the review of drugs intended to treat pediatric cancers and rare tumors. Curr Opin Pediatr. 2023;35(1):48–54.

Article  PubMed  Google Scholar 

The Center for Drug Evaluation of National Medical Products Administration. Technical guidelines for real-world research to support drug development and review in children (trial). 2020. Available from: https://www.cde.org.cn/main/news/viewInfoCommon/6906389100848948deb49a484197902b. Accessed 31 Jan 2024.